Accelerating access to precision oncology trials: risk-benefit framework for local biomarker tests for patient enrollment
Using biomarker test results from a patient’s medical record or testing by a local clinical site can accelerate trial enrollment when compared with using a trial sponsor’s clinical trial assay or candidate companion diagnostic provided by central laboratories. However, doing so may create technical, operational, and regulatory complexities for sponsors. A risk-based framework can inform sponsor decisions and awareness of risks and benefits as interest in using local tests increases.
Authors
- Thomas R. Battersby
- Lindee Goh
- Simon Patrick Dearden (ORCID: https://orcid.org/0000-0002-4485-9760)
- Barbara A. Zehnbauer (ORCID: https://orcid.org/0000-0002-2438-9407)
- Scott Donald Patterson (ORCID: https://orcid.org/0000-0002-9840-4964)
- Kelly Smith Oliner (ORCID: https://orcid.org/0009-0004-5986-2710)
- Janet Yikai Jin
- Abde M. Abukhdeir (ORCID: https://orcid.org/0000-0003-1172-5819)
- S.E. Wildsmith
- Danielle Michelle Townsley (ORCID: https://orcid.org/0009-0008-6400-8841)
- Bowen Cui
- Alexander G. Kohlmann
- Elizabeth J. Shaughnessy (ORCID: https://orcid.org/0000-0002-6621-0209)
Institutions
- AstraZeneca (United Kingdom) (GB)
- Amgen (United States) (US)
- Emory University (US)
- AstraZeneca (Netherlands) (NL)
- Precision for Medicine (United States) (US)
- Gilead Sciences (United States) (US)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- npj Precision Oncology
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1038/s41698-026-01765-8
- Primary Topic
- Ethics in Clinical Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Eli Lilly and Company
- AstraZeneca
- Gilead Sciences